Liminatus Pharma, Inc.
LIMN
$0.18
$0.00-2.17%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
3/24/2026
-
Ticker Report
3/17/2026
-
The Fly
3/17/2026
-
Globe Newswire
3/12/2026
-
Ticker Report
3/4/2026
-
TipRanks Financial Blog
3/1/2026
-
Ticker Report
2/28/2026
-
Ticker Report
2/17/2026
-
The Fly
2/17/2026
-
Globe Newswire
2/11/2026
-
The Fly
2/9/2026
-
TipRanks Financial Blog
2/1/2026
-
Ticker Report
1/26/2026
-
TipRanks Financial Blog
1/9/2026
-
Ticker Report
1/4/2026
-
Ticker Report
12/23/2025
-
Ticker Report
12/13/2025
-
Ticker Report
11/25/2025
-
TipRanks Financial Blog
11/23/2025
-
Ticker Report
11/19/2025
-
Ticker Report
11/2/2025
-
Ticker Report
10/30/2025
-
GuruFocus
10/30/2025
-
Globe Newswire
8/30/2025
-
MarketBeat
8/25/2025
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, March 31, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 4 and 8 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
213 273 5453
Address
12611 Hiddencreek Way
Cerritos, CA 90703
Cerritos, CA 90703
Country
Year Founded
Business Description
Sector
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal...
more